Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15303MR)

This product GTTS-WQ15303MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Allergic asthma, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15303MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14221MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ3120MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ11594MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ4971MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ14588MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ1859MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ12904MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ785MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW